Summary: Some biochemical characteristics such as substrate specificity, substrate affinity and inhibitor sensitivity of monoamine oxidase of human blood platelets were investigated. Tyramine, tryptamine and /?-phenylethylamine were used as substrates. The apparent Michaelis constants, maximal velocity rates and I 50 for the inhibitor tranylcypromine were determined. The data were analyzed according to Lineweaver-Burk zndDixon.
Introduction
The substrate specificity and inhibitor sensitivity of monoamine oxidase (monoamine: O 2 oxidoreductase (dearninating) EC 1.4.3.4) of human blood platelets are similar to those of monoamine oxidäse type B from human brain (1^-4). Since some abnormalities in the metabolism of biogenic amines in patients with mental disorders have been postulated (5, 6 ) several investigators have tried to correlate the activity of the platelet monoamine oxidase with the symptomatology and classification of mental diseases, thereby implying that a change of platelet monoamine oxidase may reflect an alteration of brain monoamine oxidase activity. Murphy et al (7, 8) using tryptamine found that platelet monoamine oxidase activity was reduced in chronic schizophrenics as well as in bipolar depressed patients. Nies et al (9) , using benzylamine as substrate, reported *) A preliminary report of this study was presented at the 1st
European Neurosciences Meeting, Munich, September 28, 1975. an increased platelet monoamine oxidase activity during depression in schizophrenic patients. However, Friedman et al (10) and also Shaskan & Becker (11) could not detect any alteration in monoamine oxidase activity in psychiatric patients. Most studies hitherto refer to the activity of the enzyme at a single substrate concentration only, whereas enzymic kinetic constants e. g. maximal velocity rate (V) and Michaelis constant (Kĥ ave rarely been published. Data on substrate specificity, substrate affinity and inhibitor characteristics determined simultaneously are not available. According to our working hypothesis, some properties of mono·; amine oxidase and other enzymes involved in the metabolic pathway of biogenic amines might be altered in patients with manic depressive disorders. It is therefore necessary to determine AT m , K and I 50 simultaneously. Thus a differentiated method is required which can be used under clinical routine conditions.
Evidence for the existence of isoenzymes of monoamine oxidase B is very weak (12) . On the other hand, there is evidence that the enzyme has several catalytic sites (13) . We therefore used three different substrates, tyramine, tryptamine and phenylethylamine.
Tricyclics appear to influence the enzyme activity in vitro under special experimental conditions (8, 13, 14) . The effect of try cyclic antidepressive drugs on the kinetic parameters of platelet monoamine oxidase was therefore also examined.
Assay procedure of monoamine oxidase with tyramine, tryptamine and 0-phenylethylamine as substrates a) The standard assay contained in a final volume of 2.0 ml: platelet rich plasma/buffer mixture 1.2 ml; tyramine 0.02-0.1 ml (corresponding to 10 μ mo 1/1 to 50 μηιοΐ/l); 0.05 ml [ 14 CJtyramine (50 nCi, corresponding to 2.7 μιηοΐ/ΐ); tryptamine 0.025-0.1 ml (corresponding to 2.5 μιηοΐ/lto 25.5 μηιοΐ/ΐ); 0.05 ml [ 14 C]tryptamine (50 nCi, corresponding to 0.5 μιηοΐ/ΐ); •phenylethylamine 0.015 ml-0.05 ml (15 nCi to 50 nCi, corresponding to 0.7 μιηοΐ/lto 2.5 μιηοΐ/l); serotonin 0.01-0.1 ml (corresponding to 10 μηιοΐ/lto 100 μιηοΐ/ΐ); 0.05 mi t 14 C]serotonin(50 nCi, corresponding to 0.51 μπιοΐ/l); phosphate buffer 0.1 mol/1; pH 7.4. Samples were incubated in plastic tubes for 30 min (tyramine, tryptamine, serotonin), or for 20 min (phenylethylamine) at 37°C in a Dubnoff shaker under air. The reaction was stopped by the addition of 0.25 ml of 4 mol/1 HCL The mixture was transferred to 10 ml glass stoppered centrifuge tubes containing 5 ml of a toluene/ethyl acetate mixture (volumes, 2.5 ml + 2.5 ml). The samples were shaken for 10 minutes in a mechanical shaker. After centrifugation a 3.0 ml aliquot of the supernatant fluid was transferred to a scintillation counting vial containing 10 ml of a toluene scintillation cocktail. The radioactivity of samples was determined by liquid scintillation spectroscopy in a Packard liquid scintillation counter at an efficiency for 14 C of 90%. Blanks were obtained from each determination by adding HC1 to the assay mixture prior to the incubation. Protein concentrations were measured by the method of Lowry et al (15) . In control experiments it was established that platelet free plasma did not contain noteworthy monoamine oxidase activity towards the substrates mentioned. b) For the evaluation of I so the samples were preincubated for 10 min at 37°C at four different inhibitor concentrations (tranylcyprqmine from 0.02 μιηοΐ/ΐ to 0.15 μηϊοΐ/ϊ). Thereafter the enzyme activity was determined using constant substrate concentrations: tyramine 27.1 μτηοΐ/ΐ; tryptamine 10.5 μηιοΙ/1; -phenylethylamine 2.5 μπιοΐ/ΐ.
Methods
Preparation of platelet rich plasma Blood samples were collected at 9 a. m. by dropping venous ' blood (ca. 25 ml) from the cannula into plastic tubes containing 5 ml of ACD-stabilizer (USPx VIII formula B) as the anticoagulant. The samples were centrifuged for 30 minutes at 180# at 25°C. A constant aliquot of platelet rich plasma (10 ml) was removed, using a plastic syringe. Thereafter the number of platelets was counted. Aliquots of 0.2 ml platelet rich plasma were added to 1.0 ml of phosphate buffer (0.1 mol/1; pH 7.4). These platelet rich plasma buffer mixtures are stored at -20°C and used directly for monoamine oxidase determinations. Under these conditions no loss in monoamine oxidase activity could be detected within four weeks. Monoamine oxidase activities are expressed as nanomoles of deaminated products formed per 10* of platelets per hour.
Materials
Tyramine hydro chloride and tryptamine hydro chloride were obtained from EGA-Chemie, Steinheim; 0-phenylethylamine and serotonin-creatininsulfate from Merck, Darmstadt; trans-2-phenylcyclopropylamine hydrochloride (Tranylcypromine) from Sigma; |l-r4 Cltyramine hydrochloride 9.2 Ci/mol, Isidechain 2- To study the influence of amitriptyline on the I 50 of tranylcypromine, the preincubatkm was performed in the presence of amitriptyline (1 jirnol/l; 10 μηαοΐ/ΐ) and tranylcypromine, after which the procedure was continued according to b.
The Michaelis constant (K"^ and the maximal velocity rate (V) were calculated by aLineweaver-Burk diagram, the 50% inhibition (I S o) was also determined graphically by interpolation from curves of percentage inhibition against pi.
Results
Serotonin (10 μτηοΐ/ΐ), which is a good substrate for monoamine oxidase A, showed very low rate of oxidation with platelet monoamine oxidase, amounting to 1 to 2% of that with tryptamine.
As we used platelet rich plasma as the enzyme source, benzylamine was not used as a substrate, because it shows a high rate of oxidation by serum amine oxidase.
In agreement with previous studies (12,13) monoamine oxidase activity was found to be linear in LineweaverBurk plots (16) for'tyramine and tryptamine between 1 μπιοΙ/1 and 100 μτηοΐ/ΐ. With phenylethylamine, however, substrate inhibition occurs at molar concentrations higher than 10 μηκ>1/1 ( fig. 1) . Therefore, the kinetics of phenylethylamine must be determined with substrate concentrations that give a linear Lineweaver-Burk plot. Linearity was obtained even when more than 10% of the substrate was converted to product^ i. e. under conditions for which the Michaelis Menten equation is not correctly fulfilled. Figure 2 shows that the mechanism of monoamine oxidase inhibition by tranylcypromine is the same for tyramine, tryptamine, and phenylethylamine respectively. However, the Dixon plot (17) usually taken for the determination of the inhibition constant Kdoes not yield straight lines but hyperbolic ones. From such inhibition curves the K\ value cannot be graphically determined. Therefore it is better to take the fifty percent inhibition I so as an inhibitor parameter. '
As can be seen from figure 3 there is no great difference in the tranylcypromine inhibition curves and the I 50 of the three substrates for the platelet monoamine oxidase of healthy persons. Lineweaver-Burk plots for platelet monoamine oxidase activity obtained with blood samples from seven healthy persons (24-49 years) using tyramine as substrate are shown in figure 4 . This diagram demon- 
Discussion
Experimental references to platelet monoamine oxidase activity in psychiatric patients are controversial, although similar methods have been used (7) (8) (9) (10) (11) . The discrepancies could be explained to some extent by the fact that in most of the studies only one single substrate concentration was used. Figure 9 , by means of two flctive Lineweaver-Burk plots, exemplifies why such differences are possible. The steeper line symbolizes a monoamine oxid se kinetic of platelets of psychiatric patients, the other one a kinetic from control persons. If we assume that in one laboratory the enzyme activity is measured only with one substrate at the substrate concentration "x", in a second laboratory at "y"> and in a third one at "z", the conclusions would be contradictory in respect to "y". The first investigators would find higher enzyme activity in patients, the second one no change, the third one a decreased activity compared to controls.
A further source for the different findings may be the procedures of isolation and preparation of platelets. It appears, that the phospholipid content of the monoamine oxidase has a marked influence on the enzyme properties (1). Removal of monoamine oxidase from its environment by solubilisation procedures, including ultrasonic and detergent treatment of mitochondria! preparations, may result in a modification of its properties (1, 18, 19) . By treatment of purified platelet monoamine oxidase with sodium perchlorate in order to remove the phospholipids from the enzyme, a five fold increase of the Michaelis constant for phenylethylamine was observed (13) .
Phenylethylamine and serotonin are among the substrates that have been studied with platelet monoamine oxidase. Some studies have reported that the platelet monoamine oxidase which is primarily type B (12, 20) most actively deaminated phenylethylamine, but only showed low activity for serotonin (12, 21, 22) . Our results are in agreement with these findings, but they conflict with those of Youdim et al (23) who found an enzyme activity for serotonin which was more than twice as high as the activity for phenylethylamine.
We have noticed substrate inhibition for phenylethylamine in molar concentrations as low as 10 μπιοΐ/ΐ. Similar results have been found in monoamine oxidase prepared from porcine brain, where inhibition was caused by a substrate concentration of about 0.5 mmol/1 (24) . Therefore it is necessary to elucidate the kinetic behaviour of an enzyme-catalyzed reaction before starting activity measurement with fixed substrate concentrations. It is surprising that even in recent publications on monoamine oxidase activity in platelets, phenylethylamine was used in millimolar concentrations (23) . Assuming that the affinity of the monoamine oxidase to different substrates is changed in psychiatric patients, the alteration of the enzyme could be detected by the determination of the K m but not of the activity, measured at a single substrate concentration, which would simulate equal enzyme activity; however, a complete kinetic study might reveal great differences in K m and V values. To avoid incorrect interpretations it is necessary to examine K m and K of each platelet sample for several monoamine oxidase substrates. In addition to these constants we measured the I 50 (tranylcypromine) of each substrate with the implication that a change of the Michaelis constant may also reflect an alteration of the inhibition characteristic.
Recently it has been reported that besides the classical monoamine oxidase inhibitors other psychoactive drugs could have some influence on monoamine oxidase activity (13, 14, 25, 26) . Several CNS depressants such as morphine, levallorphon, barbital, and ethanol increase the deaminating catalysis of monoamine oxidase from rat brain and bovine brain in the presence of serotonin. This effect resulted in a change of K m and V. The concentrations required to be effective are about 100 μπιοΐ/ΐ. Also during long term lithium treatment, an increase in human platelet monoamine oxidase activity has been observed byBockar et al (26) . Tricyclic antidepressants inhibit monoamine oxidase in vitro (13, 14) . The amitriptyline induced inhibition of platelet monoamirie oxidase was most pronounced when phenylethylamine was used as substrate. The inhibition was much weaker using tryptamine or benzylarnine (13) .
Our results show that amitriptyline alters the Fand K m providing the concentration is higher than 10 /zmol/l; the I 50 , however, was considerably affected by amitriptyline at 10 μτηοΐ/ΐ. The plasma levels of amitriptyline during its therapeutic administration can be assumed to be not higher than about 1 /zmol/l (27) . Therefore, under clinical conditions tricyclic drugs like amitriptyline will have no noticeable influence on the parameters mentioned.
